Enliven Therapeutics, Inc.

Healthcare

NASDAQ:ELVN · NASDAQ Global Select

Market Cap $2.73B Beta 0.40 P/E (TTM) -28.4

$45.10 -0.27%

-$0.12 today

52W Low $14.79High $48.53

Vol 2.16M · Avg 1.35M

EPS (TTM) -$1.57Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+122.28%

Period High

$48.11

Period Low

$15.14

Latest

$45.10

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

$3.36B

Relay Therapeutics, Inc.

NASDAQ:RLAY

$2.80B

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

$1.71B

Atai Beckley Inc.

NASDAQ:ATAI

$1.47B

Precigen, Inc.

NASDAQ:PGEN

$1.42B

Inhibrx Biosciences, Inc.

NASDAQ:INBX

$1.36B

Immatics N.V.

NASDAQ:IMTX

$1.31B

Nektar Therapeutics

NASDAQ:NKTR

$1.18B

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

$882.49M

Sana Biotechnology, Inc.

NASDAQ:SANA

$854.36M

What is the latest ELVN filing?

The latest filing shown is SC 13D/A dated Jun 17, 2026.

How many recent filings does ELVN have?

Intrinsic Alpha currently shows 20 recent filings for ELVN.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.